New diabetes pill shows promise in early safety trial

NCT ID NCT04426474

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested an oral drug called LY3502970 in 68 adults with type 2 diabetes. The main goal was to check safety and side effects, while also measuring how the drug moves through the body and affects blood sugar. Participants took the drug or a placebo for up to 18 weeks, with frequent visits and blood tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3502970 (oral drug)
What this could lead to: If successful, this could lead to a new oral medication to help control blood sugar in people with type 2 diabetes.
What could go wrong: This is an early Phase 1 trial focused on safety, not effectiveness. The drug may cause side effects or fail to improve blood sugar in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Clinical Pharmacology of Miami

Hialeah, Florida, 33014, United States
Endeavor Clinical Trials

San Antonio, Texas, 78229, United States
Hassman Research Institute

Marlton, New Jersey, 08053, United States
Midwest Clinical Research Unit

Dayton, Ohio, 45417, United States
Profil Institut für Stoffwechselforschung

Neuss, North Rhine-Westphalia, 41460, Germany
Profil Mainz

Mainz, 55116, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.